ArticleRespiratory research2025
Regional trends and disparities of lung cancer mortality in the United States, 1999-2022: a retrospective cohort study.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Temporal trends and forecasted mortality involving lung cancer with co-listed hypertension in U.S. adults, 2000-2035.Cardio-oncology (London, England) · 2026Article
- Trends in cardiovascular mortality among lung cancer patients in the United States: a retrospective study from 1999 to 2023.Cardio-oncology (London, England) · 2026Article
- Understanding Mortality Data: A Step-by-Step Guide to CDC WONDER, Joinpoint Analysis, and Forecasting Models.Journal of epidemiology and global health · 2026Review
- Lung Cancer Diagnosis Rates in Early Detection Programs in the Mississippi Delta.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of cancer death in the US and worldwide. This study examines regional and state-level trends in lung cancer mortality in the US from 1999 to 2022.
methodsCenter for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) was used to obtain data on lung cancer mortality in people ages 25 years and older. Age-Adjusted Mortality Rate (AAMR) was calculated along with Annual Percent Change (APC) and Average Annual Percent Change (AAPC).
resultsIn general, the age-adjusted mortality rate (AAMR) for lung cancer declined from 91.4 (95% CI 91.0 to 91.9) in 1999 to 52.0 (95% CI 51.7 to 52.2) in 2022. Throughout the study, the Midwest and South regions consistently exhibited the highest mortality rates. Notably, distinct patterns emerged when analyzing mortality rates by race and gender within each region.
conclusionThis study revealed significant variations in lung cancer mortality at both regional and state levels. Recognizing these disparities is essential for healthcare policymakers and researchers to monitor progress in reducing lung cancer deaths and identifying the populations most vulnerable to this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.